Novartis sees annual sales growth of 4% until 2026_老虎社区_美港股上老虎

Novartis sees annual sales growth of 4% until 2026

Reuters2021-12-02

Swiss drugmaker Novartis is confident to reach a core margin in innovative medicines in the high 30s by 2026 and grow sales by 4% each year until the end of that period, the company said in a ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Jiaqiang
·2021-12-02
Iike
回复
2
举报
LemonTrader
·2021-12-02
Like pls
回复
3
举报
收起
- Jiaqiang:
  nice
  2021-12-02
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1170912005?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-02 14:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170912005","market":"us","top_or_hot":-1,"title":"Novartis sees annual sales growth of 4% until 2026","media":"Reuters","content":"<div>\n<p>Swiss drugmaker Novartis is confident to reach a core margin in innovative medicines in the high 30s by 2026 and grow sales by 4% each year until the end of that period, the company said in a ...</p>\n\n<a href=\"https://www.reuters.com/business/novartis-sees-annual-sales-growth-4-until-2026-2021-12-02/\">网页链接</a>\n\n</div>\n","source":"lsy1601381805984","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis sees annual sales growth of 4% until 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis sees annual sales growth of 4% until 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-02 14:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/novartis-sees-annual-sales-growth-4-until-2026-2021-12-02/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Swiss drugmaker Novartis is confident to reach a core margin in innovative medicines in the high 30s by 2026 and grow sales by 4% each year until the end of that period, the company said in a ...</p>\n\n<a href=\"https://www.reuters.com/business/novartis-sees-annual-sales-growth-4-until-2026-2021-12-02/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVS","symbol_name":"诺华","start_time":0,"source_url":"https://www.reuters.com/business/novartis-sees-annual-sales-growth-4-until-2026-2021-12-02/","article_id":"1170912005","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170912005","pubTimestamp":1638427945,"sourceInfo":{"source_id":"lsy1601381805984","name":"Reuters"},"weMediaInfo":null,"summary":"Swiss drugmaker Novartis is confident to reach a core margin in innovative medicines in the high 30s","collect":0,"end_time":0,"defaultTopTitle":"reuters.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVS":"诺华"},"translate_title":"诺华预计2026年前年销售额将增长4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":0.9},"content_text":"Swiss drugmaker Novartis is confident to reach a core margin in innovative medicines in the high 30s by 2026 and grow sales by 4% each year until the end of that period, the company said in a presentation on Thursday.\nNovartis added it had up to 20 assets in its pipeline with approval expected by 2026 that had the potential to generate at least 1$ billion in sales.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":603568473,"gmtCreate":1638429022505,"gmtModify":1638429023104,"author":{"id":"3574242390662699","authorId":"3574242390662699","name":"Jiaqiang","avatar":"https://static.tigerbbs.com/7dc0f4640424f6dc0793677877e2dbb1","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Iike","listText":"Iike","text":"Iike","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603568473","repostId":1170912005,"repostType":4,"repost":{"id":"1170912005","pubTimestamp":1638427945,"share":"https://www.laohu8.com/m/news/1170912005?lang=&edition=full","pubTime":"2021-12-02 14:52","market":"us","language":"en","title":"Novartis sees annual sales growth of 4% until 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1170912005","media":"Reuters","summary":"Swiss drugmaker Novartis is confident to reach a core margin in innovative medicines in the high 30s","content":"<p>Swiss drugmaker Novartis&nbsp;is confident to reach a core margin in innovative medicines in the high 30s by 2026 and grow sales by 4% each year until the end of that period, the company said in a presentation on Thursday.</p>\n<p>Novartis added it had up to 20 assets in its pipeline with approval expected by 2026 that had the potential to generate at least 1$ billion in sales.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis sees annual sales growth of 4% until 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis sees annual sales growth of 4% until 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-02 14:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/novartis-sees-annual-sales-growth-4-until-2026-2021-12-02/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Swiss drugmaker Novartis is confident to reach a core margin in innovative medicines in the high 30s by 2026 and grow sales by 4% each year until the end of that period, the company said in a ...</p>\n\n<a href=\"https://www.reuters.com/business/novartis-sees-annual-sales-growth-4-until-2026-2021-12-02/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVS":"诺华"},"source_url":"https://www.reuters.com/business/novartis-sees-annual-sales-growth-4-until-2026-2021-12-02/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170912005","content_text":"Swiss drugmaker Novartis is confident to reach a core margin in innovative medicines in the high 30s by 2026 and grow sales by 4% each year until the end of that period, the company said in a presentation on Thursday.\nNovartis added it had up to 20 assets in its pipeline with approval expected by 2026 that had the potential to generate at least 1$ billion in sales.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":603587636,"gmtCreate":1638428177715,"gmtModify":1638428178288,"author":{"id":"3555298390772050","authorId":"3555298390772050","name":"LemonTrader","avatar":"https://static.tigerbbs.com/385f6b70b296a1f1e75b0fd45e9e3c84","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603587636","repostId":1170912005,"repostType":4,"repost":{"id":"1170912005","pubTimestamp":1638427945,"share":"https://www.laohu8.com/m/news/1170912005?lang=&edition=full","pubTime":"2021-12-02 14:52","market":"us","language":"en","title":"Novartis sees annual sales growth of 4% until 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1170912005","media":"Reuters","summary":"Swiss drugmaker Novartis is confident to reach a core margin in innovative medicines in the high 30s","content":"<p>Swiss drugmaker Novartis&nbsp;is confident to reach a core margin in innovative medicines in the high 30s by 2026 and grow sales by 4% each year until the end of that period, the company said in a presentation on Thursday.</p>\n<p>Novartis added it had up to 20 assets in its pipeline with approval expected by 2026 that had the potential to generate at least 1$ billion in sales.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis sees annual sales growth of 4% until 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis sees annual sales growth of 4% until 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-02 14:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/novartis-sees-annual-sales-growth-4-until-2026-2021-12-02/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Swiss drugmaker Novartis is confident to reach a core margin in innovative medicines in the high 30s by 2026 and grow sales by 4% each year until the end of that period, the company said in a ...</p>\n\n<a href=\"https://www.reuters.com/business/novartis-sees-annual-sales-growth-4-until-2026-2021-12-02/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVS":"诺华"},"source_url":"https://www.reuters.com/business/novartis-sees-annual-sales-growth-4-until-2026-2021-12-02/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170912005","content_text":"Swiss drugmaker Novartis is confident to reach a core margin in innovative medicines in the high 30s by 2026 and grow sales by 4% each year until the end of that period, the company said in a presentation on Thursday.\nNovartis added it had up to 20 assets in its pipeline with approval expected by 2026 that had the potential to generate at least 1$ billion in sales.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6811993,"gmtCreate":1638429031817,"gmtModify":1638429031918,"authorId":3574242390662699,"author":{"id":3574242390662699,"authorId":3574242390662699,"name":"Jiaqiang","avatar":"https://static.tigerbbs.com/7dc0f4640424f6dc0793677877e2dbb1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":603587636,"type":1,"supId":0,"prevId":0,"content":"nice","text":"nice","html":"nice"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":16,"commentSize":2,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}